2022 - Research.com Rising Star of Science Award
Internal medicine, Lung cancer, Oncology, Cancer and Immunotherapy are his primary areas of study. Matthew D. Hellmann studies Nivolumab which is a part of Internal medicine. His Lung cancer study incorporates themes from Pembrolizumab, Clinical trial, Survival rate, Surgery and Carcinoma.
In the subject of general Pembrolizumab, his work in Atezolizumab is often linked to Monoclonal, thereby combining diverse domains of study. His work deals with themes such as Blockade, Antibiotics, Immune system and Pathology, which intersect with Cancer. In his work, Checkpoint Blockade Immunotherapy is strongly intertwined with Melanoma, which is a subfield of Immunotherapy.
Matthew D. Hellmann mainly investigates Internal medicine, Oncology, Lung cancer, Cancer research and Immunotherapy. His is doing research in Nivolumab, Cancer, Chemotherapy, Pembrolizumab and Lung, both of which are found in Internal medicine. His biological study spans a wide range of topics, including Blockade and Clinical trial.
Matthew D. Hellmann has included themes like Survival rate, Adverse effect, KRAS, Carcinoma and Biomarker in his Lung cancer study. His work in Cancer research covers topics such as T cell which are related to areas like CD8. His Immunotherapy research is multidisciplinary, incorporating perspectives in Melanoma and Retrospective cohort study, Pathology.
Matthew D. Hellmann mainly focuses on Internal medicine, Oncology, Lung cancer, Immunotherapy and Cancer. His Lung, Blockade, Adverse effect and Durvalumab study in the realm of Internal medicine interacts with subjects such as In patient. The study incorporates disciplines such as Stage, Nivolumab, Ipilimumab and Clinical trial in addition to Oncology.
His Lung cancer study which covers KRAS that intersects with Tumor progression. His research in Immunotherapy intersects with topics in Biomarker, Cancer research and CD8. His study in the fields of Cancer immunotherapy under the domain of Cancer overlaps with other disciplines such as Pandemic.
His main research concerns Lung cancer, Internal medicine, Immunotherapy, Oncology and Cancer. His research on Lung cancer concerns the broader Pathology. His studies in Immunotherapy integrate themes in fields like Pharmacokinetics, Lesion and Cancer research, Melanoma.
His studies deal with areas such as Blockade, Nivolumab, Ipilimumab and Circulating tumor DNA as well as Oncology. His work deals with themes such as Precision medicine, Clinical trial and Gene mutation, which intersect with Cancer. Matthew D. Hellmann has researched Immune checkpoint in several fields, including Cell, CD8 and Long term response.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi;Naiyer A. Rizvi;Matthew D. Hellmann;Matthew D. Hellmann;Alexandra Snyder;Alexandra Snyder;Pia Kvistborg.
Pembrolizumab for the treatment of non-small cell lung cancer
Edward B. Garon;Naiyer A. Rizvi;Rina Hui;Natasha Leighl.
The New England Journal of Medicine (2015)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan;Nicholas McGranahan;Andrew J. S. Furness;Rachel Rosenthal;Sofie Ramskov.
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
Matthew D. Hellmann;Tudor-Eliade Ciuleanu;Adam Pluzanski;Jong Seok Lee.
The New England Journal of Medicine (2018)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir;Ryma Benayed;Ronak H Shah;Aijazuddin Syed.
Nature Medicine (2017)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A Postow;Robert Sidlow;Matthew D Hellmann.
The New England Journal of Medicine (2018)
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
Bertrand Routy;Bertrand Routy;Bertrand Routy;Lisa Derosa;Lisa Derosa;Lisa Derosa;Connie P. M. Duong;Connie P. M. Duong.
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
Scott N. Gettinger;Leora Horn;Leena Gandhi;David R. Spigel.
Journal of Clinical Oncology (2015)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Robert M Samstein;Chung-Han Lee;Chung-Han Lee;Alexander N Shoushtari;Alexander N Shoushtari;Matthew D Hellmann;Matthew D Hellmann.
Nature Genetics (2019)
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
Hira Rizvi;Francisco Sanchez-Vega;Konnor La;Walid Chatila.
Journal of Clinical Oncology (2018)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: